Company: GIFLF
Filing Date: 2025-05-12
Form Type: 6-K
Source: 0001104659-25-047168
Chunk: 9

Company: Grifols SA
Filing Date: 2025-05-12
Form: 6-K
Chunk 9
---
 the phasing of Rabies +17.5% - 8.9% +2.3% +9.6% +13.2% - 9.4% +1.0% +6.6% LFL Reported Growths at constant currency (CC) Note: All figures are presented on a consolidated basis (including Biotest), and at constant currency (cc), excluding exchang e r ate fluctuations over the period. See Annex for reconciliations. 1 Like For Like (LFL) excludes the impact of IRA (EUR 28 million) and Fee - For - Service / GPO reclassification (EUR 15 million). See Annex for reconciliations.

- 8 - Q1 2025 Results IG Growing Ahead of Market , supported by differentiated portfolio Source: Global Market Insights Immunoglobulin Market Size by Product. LTM: Last Twelve Months (LTM). 1 Like For Like (LFL) excludes the impact of IRA (EUR 28 million) and Fee - For - Service / GPO reclassification (EUR 15 million). See Annex for reconciliations, 2 Only ~10 - 30% PID patients are diagnosed, preval ence of SID is 30x > PID. Source: Primary Immunodeficiencies (PID) – driving diagnosis for optimal care in Europe, European Refe rence Paper. 3 Not yet approved in the US. 4 US IG consumption per capita is 3x than EU countries Business Performance Financials Final Remarks Annex IVIG Revenue Growth LFL 1 Base indexed to LTM Q1’24 LTM Q1'24 LTM Q2'24 LTM Q3'24 LTM Q4'24 LTM Q1'25 SCIG Revenue Growth LFL Base indexed to LTM Q1’24 LTM Q1'24 LTM Q2'24 LTM Q3'24 LTM Q4'24 LTM Q1'25 +16% LTM Q1’25 +68% LTM Q1’25 Low diagnosis and treatment rate in approved indications (especially PID 2 and SID 3 ) Low IG use per capita in many Ex - US regions 4 IgG potential beyond approved indications IVIG and SCIG Performance Market Growth Fundamentals Build on Grifols Leading Brands Lead growth in immunodeficiencies IG Uniquely Positioned Maintain Leadership in CIDP Continue to drive profitable Ex - US growth

- 9 - Q1 2025 Results Gr